Candel Therapeutics, Inc. (Nasdaq: CADL) has initiated a global pivotal phase 3 clinical trial, called AURORA, evaluating its investigational therapy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE